‘Global Public Health Partnering 2014-2019: Deal trends, players and financials’ provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered into by the worlds leading healthcare companies.
Health Partnering 2014 to 2019’ provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
- Trends in Public Health partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Public Health partnering agreement structure
- Public Health partnering contract documents
- Top Public Health deals by value
- Most active Public Health dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Public Health dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Public Health dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Public Health deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Public Health deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2014. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.
‘Global Public Health Partnering 2014 to 2019’ is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.
‘Global Public Health Partnering 2014 to 2019’ includes:
- Trends in Public Health dealmaking in the biopharma industry since 2014
- Analysis of Public Health deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Public Health deal contract documents
- Comprehensive access to over 200 Public Health deal records
- The leading Public Health deals by value since 2014
- Most active Public Health dealmakers since 2014
The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.
In ‘Global Public Health Partnering 2014 to 2019’, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Public Health Partnering 2014-2019 report’ provides comprehensive access to available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in Public Health dealmaking
- 2.1. Introduction
- 2.2. Public Health partnering over the years
- 2.3. Public Health partnering by deal type
- 2.4. Public Health partnering by industry sector
- 2.5. Public Health partnering by stage of development
- 2.6. Public Health partnering by technology type
- 2.7. Public Health partnering by therapeutic indication
Chapter 3 -Financial deal terms for Public Health partnering
- 3.1. Introduction
- 3.2. Disclosed financials terms for Public Health partnering
- 3.3. Public Health partnering headline values
- 3.4. Public Health deal upfront payments
- 3.5. Public Health deal milestone payments
- 3.6. Public Health royalty rates
Chapter 4 - Leading Public Health deals and dealmakers
- 4.1. Introduction
- 4.2. Most active in Public Health partnering
- 4.3. List of most active dealmakers in Public Health
- 4.4. Top Public Health deals by value
Chapter 5 - Public Health contract document directory
- 5.1. Introduction
- 5.2. Public Health partnering deals where contract document available
Chapter 6 - Public Health dealmaking by therapeutic target
- 6.1. Introduction
- 6.2. Deals by Public Health therapeutic target
- Appendix 1 - Directory of Public Health deals by company A-Z 2014 to 2019
- Appendix 2 - Directory of Public Health deals by deal type 2014 to 2019
- Appendix 3 - Directory of Public Health deals by stage of development 2014 to 2019
- Appendix 4 - Directory of Public Health deals by technology type 2014 to 2019
- Further reading on dealmaking
- Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent report titles from CurrentPartnering
Table of figures
- Figure 1: Public Health partnering since 2014
- Figure 2: Public Health partnering by deal type since 2014
- Figure 3: Public Health partnering by industry sector since 2014
- Figure 4: Public Health partnering by stage of development since 2014
- Figure 5: Public Health partnering by technology type since 2014
- Figure 6: Public Health partnering by indication since 2014
- Figure 7: Public Health deals with a headline value
- Figure 8: Public Health deals with upfront payment values
- Figure 9: Public Health deals with milestone payment
- Figure 10: Public Health deals with royalty rates
- Figure 11: Active Public Health dealmaking activity- 2014 to 2019
- Figure 12: Top Public Health deals by value since 2014